AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00247676
Drug: Sunitinib (SU011248)
DrugBank: Sunitinib (DB01268)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Sunitinib 50 mg by oral capsule, daily for 4 weeks in every 6 week cycle until progression or unacceptable toxicity.
Trial: NCT00662649
Drug: Fingolimod 0.5 mg
RxNorm normalized name: fingolimod 0.5 MG
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients self-administered fingolimod 0.5 mg capsules orally once daily.
Trial: NCT00662649
Drug: Fingolimod 1.25 mg
DrugBank: Fingolimod (DB08868)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Patients self-administered fingolimod 1.25 mg capsules orally once daily.
Trial: NCT00440349
Drug: Tamoxifen
RxNorm normalized name: Tamoxifen
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00440349
Drug: Prednisone
RxNorm normalized name: Prednisone
DrugBank: Prednisone (DB00635)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03232593
Drug: Atezolizumab
RxNorm normalized name: Atezolizumab
DrugBank: Atezolizumab (DB11595)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Participants will receive atezolizumab as per the local label and standard of care at physician's discretion.
Trial: NCT02930044
Drug: IV fluid repletion
RxNorm normalized name: amniotic fluid (bovine)
DrugBank: Human Amniotic Fluid (DB15871)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% NaCl or Plasmalyte A will be initiated as a continuous infusion for volume repletion. Fluids will be switched to contain potassium if serum potassium is less than 3.3 mEq/L. Fluids will be switched to contain dextrose if the serum glucose is less than 250 mg/dL.
Trial: NCT01299012
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Liraglutide s/c 0.6mg once daily.
Trial: NCT01553357
Drug: Lenalidomide, dexamethasone
DrugBank: Lenalidomide (DB00480)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Enrolled patients received lenalidomide at a dose of 25 mg/d for 21 days and oral dexamethasone at a dose of 40 mg on days 1, 8, 15, and 22 for each 28-day cycle. After 4 cycles, responding patients not eligible for SCT continued until 8 cycles of full-dose LD, if tolerated, followed by a maintenance dose of single agent lenalidomide equal to 10 mg/d on days 1-21 of each 28-day cycle.~Patients responding after 4 cycles and eligible for SCT proceeded according to single Centre transplant policy. Patients not responding after 4 cycles or progressing during this treatment were considered off-study.
Trial: NCT02411825
Drug: metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form: tablet~Route of administration: oral
Trial: NCT03399513
Drug: Ibrutinib Oral Capsule [Imbruvica]
RxNorm normalized name: ibrutinib Oral Capsule [Imbruvica]
DrugBank: Rutin (DB01698)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Imbruvica 140 mg hard capsules (Active substance: Ibrutinib)
Trial: NCT04342819
Drug: SGLT2 inhibitor
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sodium-Glucose Like Transporter 2 Inhibitor
Trial: NCT04584684
Drug: 1.5% w/v Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT04584684
Drug: 0.5% w/v Povidone-iodide
DrugBank: Povidone (DB11061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT04584684
Drug: 0.075% Cetylpyridinium Chloride
DrugBank: Cetylpyridinium (DB11073)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Over-the-counter antiseptic mouth rinse
Trial: NCT01101815
Drug: Oral Naltrexone
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 mg/day-oral
Trial: NCT01101815
Drug: Naltrexone Implant
DrugBank: Naltrexone (DB00704)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: monthly-implant
Trial: NCT01055756
Drug: Loratadine + Pseudoephedrine sulfate
RxNorm normalized name: loratadine / pseudoephedrine
DrugBank: Loratadine (DB00455)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Loratadine (5 mg) + Pseudoephedrine sulfate (120 mg)
Trial: NCT02009722
Drug: Morphine
RxNorm normalized name: Morphine
DrugBank: Morphine (DB00295)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Duramorph is administered as part of spinal anesthesia for post-operative pain relief.
Trial: NCT02009722
Drug: Hydromorphone
RxNorm normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydromorphone (Dilaudid) is administered in the intrathecal space for post-operative pain control
Trial: NCT04629378
Drug: Meropenem Injection
RxNorm normalized name: meropenem Injection
DrugBank: Meropenem (DB00760)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Meropenem IV 6 grams
Trial: NCT04629378
Drug: Amoxicillin Clavulanate
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amx/CA oral 1000/62.5mg 2 tablets
Trial: NCT04629378
Drug: Pyrazinamide
RxNorm normalized name: Pyrazinamide
DrugBank: Pyrazinamide (DB00339)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 20-30mg/kg
Trial: NCT04629378
Drug: Bedaquiline
RxNorm normalized name: Bedaquiline
DrugBank: Bedaquiline (DB08903)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Bedaquiline 400mg
Trial: NCT03367195
Drug: Omeprazole
RxNorm normalized name: Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 Omeprazole 20 mg capsules twice daily
Trial: NCT03367195
Drug: Placebo capsule of Omeprazole
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 placebo capsule of omeprazole, twice daily
Trial: NCT01809912
Drug: Recombinant human apolipoprotein(a) Kringle V
RxNorm normalized name: Recombinant human apolipoprotein A-I/phospholipid complexes
DrugBank: CER-001 (DB18538)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00545714
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fludarabine 25 mg/m\^2 as IV infusion will be administered on Days 1-3 of first six 28-day cycles.
Trial: NCT00545714
Drug: Rituximab
RxNorm normalized name: Rituximab
DrugBank: Rituximab (DB00073)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Rituximab 375 mg/m\^2 as IV infusion will be administered on Day 0 of Cycle 1; 500 mg/m\^2 as IV infusion will be administered on Day 1 of Cycle 2-6; and 375 mg/m\^2 as IV infusion every 2 months from 3 months after Day 1 Cycle 6 up to a total of 18 doses or up to 3 years after Cycle 6.
Trial: NCT01690702
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01690702
Drug: nab-Paclitaxel
RxNorm normalized name: NAB-PACLITAXEL COMPONENT PACLITAXEL
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT01690702
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03997812
Drug: VVZ-149 Injections
RxNorm normalized name: Vvz-149 free base
DrugBank: Opiranserin (DB16271)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV infusion of 1000 mg of VVZ-149
Trial: NCT00485511
Drug: Hydroxyurea
RxNorm normalized name: Hydroxyurea
DrugBank: Hydroxyurea (DB01005)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00771498
Drug: Lopinavir
RxNorm normalized name: Lopinavir
DrugBank: Lopinavir (DB01601)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ARV treatment: 2 NRTIs + lopinavir/r 800mg / 200 mg (4 tablets of Kaletra) every 12 hours, daily and orally Antituberculosis treatment: rifampin (600 mg/daily) + isoniazide (400 mg/daily) for 6 months, both in fasting condition + pirazinamide (2000 mg) for the first two months
Trial: NCT01618448
Drug: Tolvaptan
RxNorm normalized name: Tolvaptan
DrugBank: Tolvaptan (DB06212)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tolvaptan 15mg once daily
Trial: NCT03765450
Drug: Infliximab
RxNorm normalized name: Infliximab
DrugBank: Infliximab (DB00065)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Patients will receive infliximab at the discretion of their physician as part of standard of care.
Trial: NCT00458744
Drug: talotrexin
RxNorm normalized name: Talotrexin
DrugBank: Talotrexin (DB06178)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04176250
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TBA-7371 oral suspension 100 milligram (mg) once daily (QD) for 14 days.
Trial: NCT04176250
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TBA-7371 oral suspension 100 mg twice daily (BID) for 14 days.
Trial: NCT04176250
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TBA-7371 oral suspension 200 mg QD for 14 days.
Trial: NCT04176250
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TBA-7371 oral suspension 100 mg three times daily (TID) for 14 days.
Trial: NCT04176250
Drug: TBA-7371
RxNorm normalized name: TBA-7371
DrugBank: TBA-7371 (DB16243)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive TBA-7371 oral suspension 400 mg QD for 14 days.
Trial: NCT04176250
Drug: HRZE
RxNorm normalized name: Isoniazid, Rifampicin, Pyrazinamide, Ethambutol
DrugBank: Ethambutol (DB00330)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive Isoniazid \[H\] / rifampicin \[R\] / pyrazinamide \[Z\] / ethambutol \[E\] (HRZE), a fixed dose combination tablet QD for 14 days, based on weight as 40-54 kilograms (kg): 3 tablets; 55-70 kg: 4 tablets and 71 kg and over: 5 tablets.
Trial: NCT00633997
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: 50 mg orally twice daily for 10 days (last dose morning of day 10)
Trial: NCT00633997
Drug: Vildagliptin
RxNorm normalized name: Vildagliptin
DrugBank: Vildagliptin (DB04876)
FDA approved: no
EMA approved: yes
PMDA approved: no
Trial: NCT01623908
Drug: Zoledronate
RxNorm normalized name: Zoledronate
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 4mg, IV (in the vein) every 6 months. Number of Cycles: up to the researcher or until unacceptable toxicity develops.
Trial: NCT00095446
Drug: insulin aspart
RxNorm normalized name: Insulin Aspart
DrugBank: Insulin aspart (DB01306)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT00264901
Drug: insulin detemir
RxNorm normalized name: Insulin Detemir
DrugBank: Insulin detemir (DB01307)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT01639157
Drug: Buspirone
RxNorm normalized name: Buspirone
DrugBank: Buspirone (DB00490)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Subjects will be maintained on oral buspirone (10 mg administered 3 times daily) for 6 days each during the study in random order.
Trial: NCT04347733
Drug: Triamcinolone Acetonide 40mg/mL
RxNorm normalized name: TRIAMCINOLONE ACETONIDE 40MG/ML INJ,SUSP
DrugBank: Triamcinolone (DB00620)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Trial: NCT04347733
Drug: Hyaluronidase Injection
RxNorm normalized name: hyaluronidase Injection
DrugBank: Hyaluronidase (ovine) (DB00070)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: We aimed to examine the therapeutic efficacy of the combination of hyaluronidase and steroid injection for adhesive capsulitis and to determine whether such a combination therapy might enable the total amount of steroids to be reduced.
Trial: NCT03172871
Drug: Aripiprazole IM Depot
RxNorm normalized name: Aripiprazole
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Aripiprazole IM depot 400 mg/300 mg (when not tolerated)
Trial: NCT03172871
Drug: Aripiprazole tablet
RxNorm normalized name: Aripiprazole Tablets
DrugBank: Aripiprazole (DB01238)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Oral aripiprazole tablets 10 to 20 mg daily
Trial: NCT00564421
Drug: epinastine nasal spray, low concentration, low dose volume
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 sprays in each nostril, dosed twice a day
Trial: NCT00564421
Drug: epinastine nasal spray, low concentration, high dose volume
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 sprays in each nostril, dosed twice a day
Trial: NCT00564421
Drug: epinastine nasal spray, high concentration, low dose volume
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 sprays in each nostril, dosed twice a day
Trial: NCT00564421
Drug: epinastine nasal spray, high concentration, high dose volume
DrugBank: Epinastine (DB00751)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 2 sprays in each nostril, dosed twice a day
Trial: NCT02852252
Drug: ICG
RxNorm normalized name: ICG136
DrugBank: Water (DB09145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be given imaging agent 24 hours before surgery to assist in imaging.
Trial: NCT00355888
Drug: MBP-426
RxNorm normalized name: MBP
DrugBank: Myelin basic protein (DB16952)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dose escalation starting at 6 mg/m2, IV (in the vein) on Day 1 of each 21-day cycle. Number of Cycles: Up to 6 cycles, until unacceptable toxicity, disease progression, or intercurrent illness requires treatment discontinuation. Patients may continue treatment beyond 6 cycles if the Investigator determines that additional treatment would provide further benefit for the patient as long as toxicity remains acceptable.
Trial: NCT00367653
Drug: Mefloquine
RxNorm normalized name: Mefloquine
DrugBank: Mefloquine (DB00358)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Mefloquine 1250 mg PO given as a split dose (750 mg \[three 250 mg capsules\]) initial dose followed by 500 mg PO (two 250 mg capsules) given 6 to 10 hours later on Day 0
Trial: NCT00978016
Drug: arbaclofen placarbil-Cohort 1
RxNorm normalized name: baclofen 1 MG/ML
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg QD) for 7 weeks including titration and taper periods
Trial: NCT00978016
Drug: arbaclofen placarbil-Cohort 2
RxNorm normalized name: baclofen 2 MG/ML
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 40 mg QD) with for 7 weeks including titration and taper periods
Trial: NCT00978016
Drug: arbaclofen placarbil-Cohort 3
RxNorm normalized name: Baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 20 mg BID) for 7 weeks including titration and taper periods
Trial: NCT00978016
Drug: arbaclofen placarbil-Cohort 4
RxNorm normalized name: baclofen
DrugBank: Baclofen (DB00181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: After the 4 week screening period, eligible subjects will be randomized to adjunctive study treatment (arbaclofen placarbil 30 mg BID) for 7 weeks including titration and taper periods
Trial: NCT02111096
Drug: Sitagliptin
RxNorm normalized name: Sitagliptin
DrugBank: Sitagliptin (DB01261)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT02111096
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally
Trial: NCT05024825
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients in the gabapentin arm may at any point call the Pediatric ENT clinic if pain is not adequately controlled. Patients will be prescribed hydrocodone acetaminophen solution 7.5mg-325mg/15mL 5mL for ages 12-14 yrs and 10 mL for ages 15-18yrs, q 4-6 hours as needed for pain. Patients will be informed to stop taking gabapentin.
Trial: NCT04659369
Drug: Nivolumab
RxNorm normalized name: Nivolumab
DrugBank: Nivolumab (DB09035)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: for injection only
Trial: NCT02766335
Drug: Docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT02271295
Drug: Enoxaparine
RxNorm normalized name: enoxaparin
DrugBank: Enoxaparin (DB01225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparine 4000UI/day during 24 months
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 0.1 g/kg (1/4 of TDL) on Day 1 and 8, 0.2 g/kg (1/2 of TDL) on Day 15, 0.3 g/kg (3/4 of TDL) on Day 29 followed by 0.4 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 0.25 g/kg (1/4 of TDL) on Day 1 and 8, 0.5 g/kg (1/2 of TDL) on Day 15, 0.75 g/kg (3/4 of TDL) on Day 29 followed by 1.0 g/kg (full TDL) on Day 50 in Ramp-Up dosing manner.
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 0.2 g/kg (1/2 of TDL) on Day 1 and 15, followed by 0.4 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 0.5 g/kg (1/2 of TDL) on Day 1 and 15, followed by 1.0 g/kg (full TDL) on Day 29 and 57 in Ramp-Up dosing manner.
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 0.4 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Trial: NCT04578535
Drug: HYQVIA
RxNorm normalized name: Hyqvia
DrugBank: Human immunoglobulin G (DB00028)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants received a SC infusion of HYQVIA 1.0 g/kg (full TDL) SC infusion on Day 1, 29 and 57 without Ramp-Up dosing manner.
Trial: NCT00825786
Drug: Ropivacaine
RxNorm normalized name: Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ropivacaine (15 ml).
Trial: NCT00825786
Drug: Mepivacaine
RxNorm normalized name: Mepivacaine
DrugBank: Mepivacaine (DB00961)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One syringe will contain mepivacaine (15 ml)
Trial: NCT03557112
Drug: Nimotuzumab
RxNorm normalized name: nimotuzumab
DrugBank: Nimotuzumab (DB06192)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TPF Regimen Induction Chemotherapy combined with nimotuzumab concurrent radiotherapy concurrent chemoradiotherapy
Trial: NCT03557112
Drug: Cisplatin
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: TPF Regimen Induction Chemotherapy combined with cisplatin concurrent radiotherapy concurrent chemoradiotherapy
Trial: NCT02756611
Drug: Venetoclax
RxNorm normalized name: Venetoclax
DrugBank: Venetoclax (DB11581)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Tablets for oral administration
Trial: NCT01470092
Drug: Tibolone
RxNorm normalized name: TIBOLONE
DrugBank: Tibolone (DB09070)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
Trial: NCT02023931
Drug: Broccoli Sprout Extract (BSE)
RxNorm normalized name: broccoli sprout extract
DrugBank: Broccoli (DB10511)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. The first regimen will involve oral delivery and ingestion of 600 μmole doses of glucoraphanin-rich BSE (GRR-BSE), and will represent systemic delivery of sulforaphane to oral mucosa, due to the necessity to metabolize GRR-BSE in the gut.~2. The second regimen will involve oral delivery and ingestion of 100 μmole doses of sulforaphane-rich BSE (SFR-BSE), which will represent a combination of systemic and topical delivery to the oral mucosa.~3. The third regimen will isolate topical exposure of the oral mucosa to sulforaphane. Participants will swish, hold, then spit 100 μmole doses of SFR-BSE. This regimen (SFR-BSE(T)) will theoretically isolate the pharmacodynamic impact of topical exposure of the oral mucosa to sulforaphane.
Trial: NCT02127749
Drug: Vancomycin, Metronidazole, Ciprofloxacin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ciprofloxacin 500mg 2 times per day, vancomycin 500mg 3 times per day metronidazole 500mg 3 times per day All together during 7 days
Trial: NCT00926354
Drug: AS101
RxNorm normalized name: Amifostine
DrugBank: Amifostine (DB01143)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: intravenous infusions of 3mg/m2 AS101 twice a week in addition to the standard chemotherapy regimen during the following 4 chemotherapy courses.
Trial: NCT02187536
Drug: Telmisartan
RxNorm normalized name: Telmisartan
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02187536
Drug: Telmisartan placebo
DrugBank: Telmisartan (DB00966)
FDA approved: yes
EMA approved: no
PMDA approved: no